Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.
Location: United States, Connecticut, Westport
Employees: 1-10
Total raised: $10M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | VCapital | vcapital.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.06.2016 | Series A | $10M | - |
Mentions in press and media 8
| Date | Title | Description |
| 04.09.2024 | Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies... |
| 09.07.2024 | Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma | Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn., July 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity&quo... |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |
| 02.11.2018 | Intensity Therapeutics Raises $6.5 Million in Series B | WESTPORT, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series... |
| 02.11.2018 | Intensity Therapeutics Raises $6.5 Million in Series B | WESTPORT, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series... |
| 29.06.2016 | Intensity Therapeutics Nets $10M | WESTPORT, CT, Intensity Therapeutics, a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that it has secured $10 million in new capital from a Series A preferred stock financing. ... |
| 28.06.2016 | Intensity Therapeutics Raises $10 Million | WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that it has secured $10 million in new capital from a Series A pref... |
| 28.06.2016 | Biotechnology Company Intensity Therapeutics Secures $10M in Series A Financing | Intensity Therapeutics, Inc., a Westport, CT-based biotechnology company developing proprietary cancer immunotherapy products, secured $10m in Series A financing. Backers included Batterson Venture Capital, VCapital, FastForward Innovations... |